ATE478950T1 - Verfahren und zusammensetzungen zum nachweis von immunantworten - Google Patents

Verfahren und zusammensetzungen zum nachweis von immunantworten

Info

Publication number
ATE478950T1
ATE478950T1 AT06759339T AT06759339T ATE478950T1 AT E478950 T1 ATE478950 T1 AT E478950T1 AT 06759339 T AT06759339 T AT 06759339T AT 06759339 T AT06759339 T AT 06759339T AT E478950 T1 ATE478950 T1 AT E478950T1
Authority
AT
Austria
Prior art keywords
compositions
methods
immune responses
detecting immune
detecting
Prior art date
Application number
AT06759339T
Other languages
English (en)
Inventor
Kelledy Manson
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE478950T1 publication Critical patent/ATE478950T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT06759339T 2005-05-05 2006-05-05 Verfahren und zusammensetzungen zum nachweis von immunantworten ATE478950T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67832905P 2005-05-05 2005-05-05
PCT/US2006/017765 WO2006122050A2 (en) 2005-05-05 2006-05-05 Methods and compositions for detecting immune responses

Publications (1)

Publication Number Publication Date
ATE478950T1 true ATE478950T1 (de) 2010-09-15

Family

ID=37076299

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06759339T ATE478950T1 (de) 2005-05-05 2006-05-05 Verfahren und zusammensetzungen zum nachweis von immunantworten

Country Status (7)

Country Link
US (2) US8703484B2 (de)
EP (1) EP1885852B1 (de)
AT (1) ATE478950T1 (de)
AU (1) AU2006244151B2 (de)
CA (1) CA2607581A1 (de)
DE (1) DE602006016433D1 (de)
WO (1) WO2006122050A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2128612T3 (da) * 2006-09-05 2011-07-18 Hvidovre Hospital IP-10-baseret immunologisk monitorering
AU2012244350B2 (en) * 2006-09-05 2013-08-15 Statens Serum Institut Ip-10 based immunological monitoring
RU2479848C1 (ru) * 2011-12-23 2013-04-20 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения и социального развития Российской Федерации Способ прогнозирования течения увеитов, ассоциированных с ревматическими заболеваниями, у детей в условиях терапии ингибиторами фактора некроза опухоли альфа по поводу основного заболевания
WO2013172926A1 (en) * 2012-05-14 2013-11-21 Yale University Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756038B1 (en) * 1997-10-10 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
EP1461073B1 (de) 2001-11-30 2010-01-06 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Peptidagonisten für prostata-spezifisches antigen und ihre verwendung

Also Published As

Publication number Publication date
AU2006244151A1 (en) 2006-11-16
DE602006016433D1 (de) 2010-10-07
AU2006244151B2 (en) 2012-05-17
US20140213479A1 (en) 2014-07-31
CA2607581A1 (en) 2006-11-16
US20090023174A1 (en) 2009-01-22
EP1885852A2 (de) 2008-02-13
EP1885852B1 (de) 2010-08-25
US8703484B2 (en) 2014-04-22
WO2006122050A2 (en) 2006-11-16
WO2006122050A3 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
LTC1971366I2 (lt) Žmogaus anti-IL-23 antikūnai, kompozicijos, metodai ir panaudojimai
CY1116261T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
DE602006000297D1 (de) Verbinder , Verbinderprüfgerät und Verfahren
DK2260862T3 (da) Sammensætninger og fremgangsmåder til behandling af tumorer der præsenterer survivin-antigener
MX2009004883A (es) Piridil sulfoximinas multi-substituidas y su uso como insecticidas.
NO20076003L (no) TGF-beta 1 spesifikke antistoffer
DK3156069T3 (da) Sammensætninger, fremgangsmåder, og kits til fremkaldelse af et immunrespons
DE602005025745D1 (de) Markierte abstützmittel und verwandte verfahren
DE602005014628D1 (de) Embolie-teilchen
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
DE602006005211D1 (de) HARQ-Verfahren und -System
WO2008031041A3 (en) Melanoma gene signature
BRPI0506777A (pt) antagonistas do receptor muscarìnico da acetilcolina
ATE549416T1 (de) Verfahren und zusammensetzungen zum nachweis von autoimmunkrankheiten
DE602006020904D1 (de) Verfahren zum testen von antigen
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
NO20083609L (no) Fremgangsmater og sammensetninger for malrettet-RELT
ATE478950T1 (de) Verfahren und zusammensetzungen zum nachweis von immunantworten
DE112006003301B8 (de) Brennstoffzellensystem und Verfahren zum Stoppen des Betriebs desselben
DE602006010187D1 (de) Einzelsequenzhybridisierungssonden
DE602006010035D1 (de) Vorrichtung zum modifizieren von brennstoff
ATE551605T1 (de) Verfahren und vorrichtungen zur erkennung von biofilmen
ATE474462T1 (de) Zusammensetzungen, kits und verfahren, bei denen eine zugesetzte borquelle eingesetzt wird
DE502006002735D1 (de) Vorrichtung zum fördern von kraftstoff

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties